Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.
about
Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic originENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromesCurrent and Future Theranostic Applications of the Lipid-Calcium-Phosphate Nanoparticle Platform.Human Anti-Oxidation Protein A1M--A Potential Kidney Protection Agent in Peptide Receptor Radionuclide TherapyApplication and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine TumorsNon-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and managementFrom targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumorsClinical applications of Gallium-68Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoidsManagement of patients with hepatic metastases from neuroendocrine tumorsSummary of emerging personalized medicine in neuroendocrine tumors: are we on track?Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumoursNeuroendocrine tumors of the gastro-entero-pancreatic systemStreptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment StratificationNew therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: a single centre experienceRadioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma.High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.Progress in the treatment of neuroendocrine tumors.Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategyEfficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis.Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature.Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapiesConsensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group.Radiolabeled regulatory peptides for imaging and therapyAssessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT).New treatment options for patients with advanced neuroendocrine tumors.Outpatient therapeutic nuclear oncology.ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors.ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Gastric neuroendocrine tumours.Therapy for metastatic pancreatic neuroendocrine tumors.Neuroendocrine tumors of the small bowels are on the rise: Early aspects and management.Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group.Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors.
P2860
Q21296729-7B0BD345-044F-47E8-96DC-0898355B9692Q24603675-985C4FB8-3AF6-4CBE-B49B-56DC864FAA82Q26746186-4205339E-DCBE-4D56-863F-AD9667DC012CQ26773377-F9F98A86-07DF-455B-9E8B-3F8AA9239932Q26783272-C2A9C69D-EDA7-4238-80A0-6347B96FFCCCQ26795597-0A006C29-222A-4802-B8E6-C4039B63D296Q26822011-73BCB958-4220-4A00-AC23-965A7F147F9BQ26849276-7DCA8A77-C0E1-48B4-B026-4A023E53B8CBQ26996521-E5AB5B56-05FD-49A4-8AA1-C33D99D2238CQ27008832-5B310F3D-3F2A-4E2C-A471-F433C0D36972Q28078610-C2476A4A-C3B1-42A8-B951-B9DC9E983D75Q28247667-B5D29DB0-6861-43FB-A89E-2FD8D850A14EQ28294432-0F607A5D-1C4D-45EF-9B82-64CF84916700Q28551275-09D72CD2-BFA8-4EE0-93ED-B4BE23AE7AE1Q30364864-C66F16D9-74B3-4ABE-BB92-7E2B364A6061Q33392694-25AF99A8-AA5B-4BA1-8417-E881FC51AC77Q33397018-15F789F8-35AF-42F7-B0CD-6C14EBF8E664Q33403035-FF4674F9-BF23-41D2-90AD-E96E110AE720Q33412734-85519513-4F32-4239-B1AD-7EECEA55D80DQ33435622-E3CA8DCB-8639-47FC-82FD-A4EB2412B8DEQ33438326-98F788F1-EDFA-4F6C-A2A8-6688D967757BQ33643643-494D51AD-97BB-4DEB-B9C0-9A8B2A903815Q33669457-34477352-8C2C-41E8-979C-95BBD90A4E7FQ33700134-E6891382-1858-4954-BA21-44453E626FFEQ33737587-69C65D89-0BF2-418A-AE4E-0F92FE6839F3Q33840177-83C3DA67-E5CB-44E2-85E4-B65A9A1550DCQ33894587-BC881355-BC9B-4BC8-8601-E0D612778370Q33941027-7F2BE5FD-7F9E-4DE7-B012-25A53140F4B8Q34157391-C92F3F81-BA8B-4BA8-B5C3-CDA820E617A3Q34173336-6A2DDE2F-749D-43D3-8D62-F73B735F997AQ34244990-704C9386-0395-4D25-ACA7-A41DB7CD5614Q34248466-5CA4F13A-4C55-46ED-8E3D-07B1F239BD4AQ34248487-C24E3866-721C-46EC-A329-7AAEF818CBC7Q34256413-AEF88B66-D0A8-4A53-A408-B84E07AE9F45Q34301030-7A3D1E26-BCE9-417D-8241-E7776016D429Q34306680-ECFA8B01-91D3-471E-B443-D407B01F4318Q34357869-61F70BE0-9589-48FF-B36C-5E52D0C66A15Q34389590-6BF71487-BBD5-4540-ADBE-59F09B37A006Q34446086-4B7E7EA4-5B70-4F6B-96BC-596CD1C0E869Q34452319-A448EA2C-3813-4B37-BB0D-6D6A3C65ADCC
P2860
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Treatment with the radiolabele ...... icity, efficacy, and survival.
@en
Treatment with the radiolabele ...... icity, efficacy, and survival.
@nl
type
label
Treatment with the radiolabele ...... icity, efficacy, and survival.
@en
Treatment with the radiolabele ...... icity, efficacy, and survival.
@nl
prefLabel
Treatment with the radiolabele ...... icity, efficacy, and survival.
@en
Treatment with the radiolabele ...... icity, efficacy, and survival.
@nl
P2093
P356
P1476
Treatment with the radiolabele ...... icity, efficacy, and survival.
@en
P2093
Boen L Kam
Casper H van Eijck
Dik J Kwekkeboom
Eric P Krenning
Maarten O van Aken
Martijn van Essen
Peter P Kooij
Richard A Feelders
P304
P356
10.1200/JCO.2007.15.2553
P407
P577
2008-05-01T00:00:00Z